Early aberrant angiogenesis due to elastic fiber fragmentation in aortic valve disease by Hinton, Robert B et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
Early aberrant angiogenesis due to elastic fiber fragmentation in 
aortic valve disease 
Robert B Hinton 
Amy L Juraszek 
Amy M Opoka 
Benjamin J Landis 
J Michael Smith 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Robert B Hinton, Amy L Juraszek, Amy M Opoka, Benjamin J Landis, J Michael Smith, Robert P Mecham, 





Early Aberrant Angiogenesis Due to Elastic Fiber Fragmentation
in Aortic Valve Disease
Robert B. Hinton 1,* , Amy L. Juraszek 2, Amy M. Opoka 1 , Benjamin J. Landis 3, J. Michael Smith 4,
Robert P. Mecham 5 and Kevin E. Bove 6


Citation: Hinton, R.B.; Juraszek,
A.L.; Opoka, A.M.; Landis, B.J.; Smith,
J.M.; Mecham, R.P.; Bove, K.E. Early
Aberrant Angiogenesis Due to Elastic
Fiber Fragmentation in Aortic Valve
Disease. J. Cardiovasc. Dev. Dis. 2021,
8, 75. https://doi.org/10.3390/jcdd
8070075
Received: 6 May 2021
Accepted: 22 June 2021
Published: 25 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Divisions of Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA;
amy.opoka@cchmc.org
2 Pediatric Cardiology, Wolfson Children’s Hospital, Jacksonville, FL 32207, USA; juraszal@gmail.com
3 Division of Pediatric Cardiology, Indiana University School of Medicine, Indianapolis, IN 46204, USA;
benjland@iu.edu
4 The Christ Hospital Heart Network, Cincinnati, OH 45219, USA; jmichaelsmith62@gmail.com
5 Department of Cell Biology and Physiology, Washington University, St. Louis, MO 63130, USA;
bmecham@wustl.edu
6 Division of Pathology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA;
kevin.bove@cchmc.org
* Correspondence: bingrbh@icloud.com; Tel.: +1-(513)-636-4200
Abstract: Elastic fiber fragmentation (EFF) is a hallmark of aortic valve disease (AVD), and neovascu-
larization has been identified as a late finding related to inflammation. We sought to characterize the
relationship between early EFF and aberrant angiogenesis. To examine disease progression, regional
anatomy and pathology of aortic valve tissue were assessed using histochemistry, immunohisto-
chemistry, and electron microscopy from early-onset (<40 yo) and late-onset (≥40 yo) non-syndromic
AVD specimens. To assess the effects of EFF on early AVD processes, valve tissue from Williams and
Marfan syndrome patients was also analyzed. Bicuspid aortic valve was more common in early-onset
AVD, and cardiovascular comorbidities were more common in late-onset AVD. Early-onset AVD
specimens demonstrated angiogenesis without inflammation or atherosclerosis. A distinct pattern
of elastic fiber components surrounded early-onset AVD neovessels, including increased emilin-1
and decreased fibulin-5. Different types of EFF were present in Williams syndrome (WS) and Marfan
syndrome (MFS) aortic valves; WS but not MFS aortic valves demonstrated angiogenesis. Aberrant
angiogenesis occurs in early-onset AVD in the absence of inflammation, implicating EFF. Elucidation
of underlying mechanisms may inform the development of new pharmacologic treatments.
Keywords: heart valves; aortic root; elastic fiber; angiogenesis; pediatrics
1. Introduction
Aortic valve disease (AVD) obstructs outflow from the heart, affects 2.5% of the general
population, and remains a significant cause of mortality [1,2]. Genetic and environmental
risk factors have been identified. The treatment for AVD continues to be primarily surgical,
restricted to late-stage disease, and the number of replacement procedures increases rapidly
with the aging population [3,4]. A central problem in the field remains the need to better
understand early AVD processes and alternative medical treatment strategies [5]. AVD
is characterized by cell and matrix abnormalities that are well established. Advances in
human genetics and developmental biology have elucidated mechanisms that contribute
to pathogenesis [6,7], but to date, early disease processes remain poorly understood, and
no pharmacologic-based treatments that directly treat AVD have been established.
Aberrant angiogenesis was originally described in cancer literature, and since then, a
fundamental role for this biologic process has been established in other disease states that
affect typically avascular tissue [8,9]. Aberrant angiogenesis has been described in non-
rheumatic AVD [10–13] and is widely interpreted to represent a secondary finding of inflam-
J. Cardiovasc. Dev. Dis. 2021, 8, 75. https://doi.org/10.3390/jcdd8070075 https://www.mdpi.com/journal/jcdd
J. Cardiovasc. Dev. Dis. 2021, 8, 75 2 of 15
mation, typically due to atherosclerosis [14,15]. However, children without atherosclerosis
develop AVD, and the potential use of 3-Hydroxy-3-Methylglutaryl coenzyme-A reductase
inhibitors (statins), an effective therapy for atherosclerosis, to treat AVD has shown no
effect on the progression of AVD or the need for aortic valve replacement [16]. The potential
role of aberrant angiogenesis in early-onset AVD pathogenesis is unknown.
Elastic fiber abnormalities have long been identified as a central finding of AVD,
including markedly diminished elastic fibers that are fragmented and dispersed through-
out the valve cusp layers [17–19]. AVD in pediatric patients is characterized by similar
extracellular matrix (ECM) disorganization, including elastic fiber fragmentation (EFF), but
without inflammation or calcification [20,21]. Both Williams (OMIM#194050) and Marfan
(OMIM#154700) syndromes, associated with mutations in the elastic fiber genes elastin
(ELN) and fibrillin-1 (FBN1), respectively, are associated with valve malformation and dis-
ease in 20–45% of cases [22,23]. The histopathology abnormalities of valves in these genetic
syndromes are distinct, but each overlap with non-syndromic AVD [23,24]. Interestingly,
it has been shown that intact elastic fibers are angiostatic, and elastic fiber fragments are
angiogenic [25,26], consistent with a potential role for EFF in the manifestation of neovas-
cularization in AVD; however, the relationship between EFF and aberrant angiogenesis in
the context of AVD is unknown.
The anatomy of the mature aortic valve is complex. There are normally three semilunar
cusps hinged to a crown-shaped collagenous annulus within the aortic root [27,28]. The
cusp extracellular matrix (ECM) organization is trilaminar (fibrosa, spongiosa, ventricularis)
with elastic fibers radially organized as filaments in the ventricularis layer [29]. Elastic
fibers consist of multiple components, including elastin, fibrillin-1, emilin, and fibulins that
are coordinately expressed throughout the valve and spatio-temporally regulated during
embryogenesis to facilitate fiber assembly in the ventricularis [30,31]. The ring spongiosa
is a subsection of the spongiosa layer located at the interface between the annulus and
cusp that functions as the hinge of the valve and consists of proteoglycans and elastic
fiber components [29,32]. Little is known about the potential role of the annulus and ring
spongiosa regions in AVD.
The objective of this study was to examine the impact of EFF in AVD progression. We
hypothesized that early AVD would be characterized by angiogenesis, which is associated
with EFF. Our findings identified EFF and aberrant angiogenesis in early-onset AVD, estab-
lishing the role of elastic fiber dysregulation in AVD pathogenesis preceding inflammation.
These studies advance our understanding of early disease processes, potentially facilitating
the identification of new pharmacologic treatments.
2. Materials and Methods
2.1. Human Valve Tissue
Aortic valve specimens were obtained from non-syndromic patients with isolated AVD
undergoing aortic valve replacement (affected), and from age-matched individuals who
died of non-cardiac causes (control) at the time of autopsy. AVD patients were stratified
by age into early-onset (0–40 yo) and late-onset (41–85 yo) groups. Patients with a history
of rheumatic heart disease or infective endocarditis were excluded. Medical records were
reviewed, and aortic valve morphology and major cardiovascular comorbidities were
noted, including coronary artery disease (CAD), essential systemic hypertension (HTN),
diabetes mellitus (DM), thoracic aortic aneurysm (TAA), and chronic kidney disease (CKD).
These studies were approved by the Institutional Review Boards at Cincinnati Chil-
dren’s Hospital Medical Center (CCHMC) and Good Samaritan Hospital (Cincinnati, Ohio).
In addition, human heart specimens were obtained from pediatric patients with either
Williams or Marfan syndrome from the Cardiac Registry at Children’s Hospital Boston;
these studies were approved by the Institutional Committee on Clinical Investigations.
For comparison purposes, whole heart specimens from age-matched patients with non-
syndromic isolated AVD (affected) and non-cardiac disease (control) were obtained from
the Teaching Collection at CCHMC.
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2.2. Histochemistry
Valve tissue was processed and analyzed as previously described [20]. Movat’s modi-
fied pentachrome stain was used to examine ECM organization and alizarin red to assess
calcification. Whole hearts were dissected precisely to demonstrate the aortic sinus equidis-
tant from the adjacent commissures and the aortic valve annulus at its most proximal
position. Comprehensive morphometrics were obtained in comparable sections, including
tissue thickness dimensions for the ascending aorta, sinotubular junction, aortic root, and
valve (hinge, proximal, distal), as well as area measurements for the annulus and ring
spongiosa regions.
2.3. Immunohistochemistry
Antibodies directed against elastic fiber components, as well as markers of angio-
genesis, inflammation, and atherosclerosis, were examined (Supplemental Material, Table
S1). A universal streptavidin/biotin and diaminobenzidine detection system (Vector) was
used for colorimetric detection, as previously described [20,21]. High heat sodium citrate
antigen retrieval was used for pretreatment of all antibodies except elastin, which used
enzymatic trypsin pretreatment. Angiogenesis was considered present if there was VEGF
immunoreactivity without neovessel formation (provisional) or with neovessel formation
(overt) [33]. Due to AVD tissue heterogeneity, a semi-quantitative assessment of VEGF
and CD-68 expression was performed using a scale described by Alexopoulous et al. [34].
Briefly, staining was graded on a scale from 0 to 3 based on the percentage of positive cells
as follows: 0–immunoreactivity in <10% of cells, 1—10–35%, 2—35–70%, and 3—>70%.
2.4. Transmission Electron Microscopy
Valve tissue ultrastructure was examined (Hitachi 7600, Hitachi, Shaumberg, IL, USA)
on epoxy resin sections from 10% NBF fixed control, WS, and MFS specimens [20]. For
visualization of collagens and elastins, sections were stained with 5% tannic acid aqueous
solution, followed by 1% uranyl acetate, and counterstained with lead citrate.
2.5. Statistical Analysis
Student’s t-test or one-way ANOVA was used to compare groups. Findings are re-
ported as the mean ± SEM. A p < 0.05 was considered significant.
3. Results
3.1. Study Population
Non-syndromic patients with AVD were stratified by age. Early-onset AVD specimens
were obtained from patients aged 1 to 32 years (n = 21) and were compared with late-
onset AVD specimens obtained from patients aged 44 to 85 years (n = 11). Both disease
groups were also compared with age-matched controls (n = 8 each) that did not have AVD.
The indication for surgery in all cases was stenosis, although some had mixed disease
(stenosis and insufficiency). Bicuspid aortic valve (BAV) was more common in early-
onset AVD, whereas cardiovascular comorbidities were more common in late-onset AVD
(Table 1), consistent with previous findings [21,35,36]. Importantly, clinically significant
atherosclerosis (CAD) was not present in any early-onset AVD case.
Aortic valve specimens from syndromic patients were obtained from WS (n = 6, mean
age 22 months), MFS (n = 4, mean age 10 months), and compared with pediatric AVD
(n = 3, mean age 12 months), and control (n = 3, mean age 5 months) patients. In addition
to the characteristic arteriopathy (supravalvar aortic stenosis, SVAS) or aortopathy (dilated
aortic root) identified in all WS and MFS cases examined, respectively, clinical evidence of
AVD was documented in three out of five (one unknown) WS patients (one with BAV) and
two out of four MFS patients (none with BAV).
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Table 1. Non-syndromic AVD study population demographics and comorbidities.
Early-Onset AVD Late-Onset AVD p
N 21 11 -
Mean Age (Range) 15 (1, 32) 67 (44, 85) -
Male (%) 81 73 NS
BAV (%) 48 27 0.08
CAD (%) 0 45 <0.003
HT (%) 10 55 <0.002
TAA (%) 10 18 NS
DM (%) 5 36 0.08
CKD (%) 0 9 <0.001
AVD, aortic valve disease; BAV, bicuspid aortic valve; CAD, coronary artery disease; CKD, chronic kidney disease;
DM, diabetes mellitus; HT, systemic hypertension; NS, not significant; TAA, thoracic aortic aneurysm.
3.2. Early-Onset AVD Specimens Demonstrate Aberrant Angiogenesis without Inflammation
or Atherosclerosis
Overt angiogenesis was present in 11/11 (100%) late-onset and 8/21 (38%) early-
onset AVD specimens. Among the early-onset AVD subgroup, 16/21 were from pediatric
patients (≤18 years old), and 4/16 (25%) showed overt angiogenesis. In both groups,
neovessels were identified in all cusp layers and the annulus with an increased proportion
of vessels recognized in the proximal aspect of the cusp, including the ring spongiosa;
however, vessels in early-onset AVD specimens were fewer in number and smaller in
diameter. Provisional angiogenesis was present to the same extent in all early- and late-
onset AVD specimens but was not detected in age-matched controls. VEGF expression is
increased in the interstitium heterogeneously in both early and late-onset AVD (Figure 1).
CD-31 identified endothelial cells associated with neovessels but only scant interstitial
cells, suggesting most VEGF-positive cells are not endothelial in origin. CD-31 positive
neovessels were quantified and stratified as microvessels or arterioles (Table 2).
Table 2. CD-31 neovessel quantification and stratification.
Microvessels Arterioles Total (Vessels/10×)
Control 0 0 0
Early AVD 0.7 0.2 0.9
Late AVD 3.7 1.9 5.6
Chondromodulin, an angiostatic factor, is decreased in all AVD specimens, as previ-
ously described [10]. Importantly, the inflammation marker CD-68 is strongly expressed in
VIC clusters spatially associated with calcific nodules in late-onset AVD but are virtually
absent from the majority of early-onset specimens, similar to controls, suggesting upregu-
lation of VEGF arose from resident cell populations. Semi-quantitative analysis for VEGF
and CD-68 is reported in Table 3. Similarly, the Wnt/beta-catenin signaling marker LRP-5,
which has been used to identify atherosclerosis, is absent from early-onset AVD and control
specimens but is strongly expressed in late-onset AVD, as previously described [14]. Provi-
sional and overt angiogenesis occur in early-onset AVD without clinical or histopathologic
evidence of inflammation or atherosclerosis.
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Figure 1. Aberrant angiogenesis in early-onset AVD precedes inflammation and atherosclerosis. 
Representative sections from control (left), early-onset AVD (center), and late-onset AVD (right) 
specimens. Normal elastic fiber structure is localized to the ventricularis layer of the cusp (arrow, 
A). Both early- and late-onset AVD are characterized by EFF and dispersion (B,C). Provisional (ar-
rowhead) and overt (arrow) angiogenesis (D) is seen in early- (E) and late-onset (F) AVD, charac-
terized in part by endothelial markers around neovessels (H,I) not observed in controls (G). Angio-
static CHM (J,K) is decreased in areas of angiogenesis in late-onset AVD (asterisk, L). Nominal CD-
68 is seen in early-onset AVD (N), similar to control (M), corresponding with no atherosclerosis as 
demonstrated by absent LRP-5 staining (P,Q), both of which were markedly increased in late-onset 
AVD (double asterisks, O,R). The ventricularis cusp layer is oriented at the bottom of all panels. 
Chondromodulin, an angiostatic factor, is decreased in all AVD specimens, as previ-
ously described [10]. Importantly, the inflammation marker CD-68 is strongly expressed 
Figure 1. Aberrant angiogenesis in early-onset AVD precedes inflammation and atherosclerosis.
Representative sections from control (left), early-onset AVD (center), and late-onset AVD (right) speci-
mens. Normal elastic fiber structure is localized to the ventricularis layer of the cusp (arrow, A). Both
early- and late-onset AVD are characterized by EFF and dispersion (B,C). Provisional (arrowhead)
and overt (arrow) angiogenesis (D) is seen in early- (E) and late-onset (F) AVD, characterized in
part by endothelial markers around neovessels (H,I) not observed in controls (G). Angiostatic CHM
(J,K) is decreased in areas of angiogenesis in late-onset AVD (asterisk, L). Nominal CD-68 is seen in
early-onset AVD (N), similar to control (M), corresp nding with no atheroscl rosis as demonstr t d
by absent LRP-5 staining (P,Q), both of which were markedly inc eased in late-onset AVD (doubl
asterisks, O,R). The ventricularis cusp layer is oriented at the bottom of all panels.
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Table 3. VIC relative expression of angiogenesis and inflammation.
VEGF-A CD-68
Score Control Early AVD Late AVD Control Early AVD Late AVD
0 (0–10% + cells) 100% 0% 18% 100% 73% 20%
1 (10–35% + cells) 0% 21% 27% 0% 18% 40%
2 (35–70% + cells) 0% 57% 36% 0% 9% 40%
3 (>70% + cells) 0% 21% 18% 0% 0% 0%
Mean (SD) 0 ± 0 2.0 ± 0.7 * 1.6 ± 1.0 * 0 ± 0 0.4 ± 0.7 1.3 ± 0.8 *,#
* p < 0.05 vs. Control; # p < 0.05 vs. Early AVD.
3.3. A Distinct Pattern of Elastic Fiber Components Is Associated with Early-Onset
AVD Neovessels
In early-onset AVD, elastic fibers are decreased, fragmented, and dispersed in general,
as previously reported in late-onset AVD [17]; however, the distribution of specific elastic
fiber components is distinct (Figure 2). Elastin is present in the fragments surrounding
neovessels, whereas fibrillin is present in the lining of the neovessels but not in the area
around them. Emilin, an elastic fiber glycoprotein that binds tropoelastin to the microfibril,
is increased in all layers and present predominantly in the area surrounding neovessels.
Fibulin-4, but not fibulin-5, is present around neovessels. Finally, LOX expression, normally
present throughout the valve but preferentially in the ventricularis layer, was not changed
in AVD specimens compared with controls and was not associated with neovessels. These
patterns were similar in early and late-onset AVD groups. Of note, some EFF was associated
with both neovessels and calcific nodules in late-onset AVD (data not shown) [37,38].
Therefore, differential expression of elastic fiber components is associated with aberrant
angiogenesis in early-onset AVD.
3.4. WS but Not MFS Aortic Valves Demonstrate Aberrant Angiogenesis
To better understand the role of EFF in AVD pathogenesis, we examined the aortic
valves from WS and MFS patients and compared them with early-onset AVD specimens
(Figure 3). All syndromic specimens examined had histopathologic evidence of AVD.
Paradoxically, elastic fiber content was markedly increased in the ventricularis layer of both
WS and MFS specimens compared with non-syndromic AVD, but patterns of elastic fiber
disorganization and fragmentation were different. Aortic valves from WS patients show
more intra-EFF (within a bundle) and dispersion, while aortic valves from MFS patients
show more inter-EFF (between bundles) and delamination. Interestingly, WS aortic valves
demonstrate angiogenesis, but MFS valves do not. Elastic fiber fragments in WS were
dispersed, whereas in MFS they were restricted to the ventricularis layer. In early-onset
AVD, there is EFF characterized by inter- and intra-fiber fragmentation, dispersion of the
fragments to all layers of the valve as well as the annulus and thinning of fibers that often
remain intact with delamination. Therefore, different patterns of EFF are observed in WS
and MFS aortic valves; each share characteristics seen in early-onset AVD .
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Figure 2. Specific elastic fiber components are associated with overt angiogenesis. Representative 
sections from control (left column, A,C,E,G,I,K) and early-onset AVD (right column, B,D,F,H,J,L) 
specimens. In control tissue, elastin and fibulin-5 are localized in the cusp ventricularis layer (ar-
rows), but fibrillin, emilin, fibulin-4, and LOX are also expressed weakly in all layers (arrowheads). 
In AVD tissue, elastin, fibrillin, emilin, and fibulin-4 are associated with neovessels (asterisk, 
B,D,F,H), whereas fibulin-5 and LOX are not (J,L). 
Figure 2. Specific elastic fiber components are associated with overt angiogenesis. Representative
sections from control (left column, A,C,E,G,I,K) and early-onset AVD (right column, B,D,F,H,J,L)
specimens. In control tissue, elastin and fibulin-5 are localized in the cusp ventricularis layer (arrows),
but fibrillin, emilin, fibulin-4, and LOX are also expressed weakly in all layers (arrowheads). In
AVD tissue, elastin, fibrillin, emilin, and fibulin-4 are associated with neovessels (asterisk, B,D,F,H),
whereas fibulin-5 and LOX are not (J,L).
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Figure 3. Elastic fiber dysregulation impacts regional aortic valve structure. Regional aortic valve 
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specimens demonstrate specific differences in matrix organization. EFF in WS and MFS is different 
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Figure 3. Elastic fiber dysregulation impacts regional aortic valve structure. Regional aortic valve
tissue (annulus, ring spongiosa, cusp) from control (A), early-onset AVD (B), WS (C), and MFS (D)
specimens demonstrate specific differences in matrix organization. EFF in WS and MFS is different
(arrows, C vs. D). Neovessels are seen in WS (arrowhead, C) but not MFS.
3.5. The Aortic Root Is Composed in Part of Valve Tissue
Comprehensive morphometrics demonstrated increased valve and aorta thickness
in WS specimens (Supplemental Material, Figure S1). Neither WS nor MFS aortic valves
demonstrated calcification (data not shown). Neovessel formation in both WS and AVD
whole heart specimens was localized to the proximal third of the cusp, the ring spongiosa,
and to a limited degree the annulus, where EFF was concentrated. In WS patients, in
addition to substantial collagen accumulation in the sinotubular junction (STJ), fibrillin and
emilin were present within the fibrous aspect of the STJ (Supplemental Material, Figure S2).
Neovessels were identified both in the fibrous STJ and the intimal aspect of the aortic media
in WS. Conversely, the STJ in MFS was completely effaced, demonstrating loss of normal
landmarks and no fibrous tissue. The aortic root demonstrated markedly more severe
disease compared with the ascending aorta in all groups, but the patterns of histopathology
were distinct by group (Supplemental Material, Figure S3). In addition to established
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findings [39], the WS specimens demonstrated more inter-EFF, whereas the MFS specimens
demonstrated more intra-EFF. In AVD, there was less pronounced aortopathy in both the
root and ascending aorta, which manifested localized areas of both inter- and intra-EFF
with modest proteoglycan accumulation. Elastic fiber dysregulation contributes to both
AVD and aortopathy, consistent with the clinical association, but there are different patterns
of EFF by tissue type.
3.6. Different Elastic Fiber Defects Result in Different Types of EFF
An ultrastructural analysis of the aortic valve annulus and cusp regions in WS and
MFS identified distinct elastic fiber abnormalities (Figure 4). In control specimens, elastic
fiber components were present in the cusp ventricularis layer organized as filaments
and the ring spongiosa in an unorganized fashion but were not present in the annulus.
WS specimens demonstrated predominantly intra-EFF in the cusp and EFF dispersion
throughout the valve, including in the annulus region, consistent with the histochemistry
described above. MFS specimens demonstrated primarily inter-EFF in the cusp and EFF
dispersion into the annulus but not the rest of the cusp. The elastin is characterized
by a “moth-eaten” edge and a decrease in surface microfibrils, consistent with classic
descriptions of fibrillin in MFS [40]. Proteoglycans were present in the annulus region
of WS specimens, but not MFS or controls. Collagen fibers were disorganized in both
WS and MFS groups by region compared with control specimens and previous regional
descriptions [32,41]. Specifically, in WS, the collagen fiber diameters were irregular and
small in the cusp region only, but in MFS, the collagen fiber diameters were irregular
and small in the annulus region. Ultrastructure analysis demonstrated a spectrum of
overlapping but with subtly distinct types of EFF in regional syndromic valve tissue,
consistent with elastase-mediated degeneration.




Figure 4. Ultrastructure of the valve annulus and cusp regions in WS and MFS. Collagen and elastic fiber organization in 
annulus (A–C) and cusp (D–F) regions from control (A,D), WS (B,E), and MFS (C,F) specimens. Cross sections of collagen 
fibril size and organization are demonstrated (insets). In control specimens, organized elastic fiber filaments are seen in 
the cusp (arrows) but not the annulus. WS specimens are characterized primarily by intra-EFF (B,E), whereas MFS has 
more inter-EFF (data not shown). There is proteoglycan accumulation in WS specimens (arrowheads, B,E) and a “moth-
eaten” edge appearance in MFS specimens (arrowheads, C and F). Collagen fibrils are small, irregular, and decreased in 
number in the cusp region of WS and the annulus region of MFS (asterisks, C and E). 
4. Discussion 
The findings of this study identify EFF and aberrant angiogenesis as early disease 
processes underlying AVD preceding the manifestation of inflammation (Figure 5). These 
results establish a central role for elastic fiber dysregulation in early AVD pathogenesis, 
suggesting that faulty elastic fiber assembly and consequent elastase-mediated tissue in-
jury contribute to disease initiation and progression. The demonstration of different types 
of EFF in WS and MFS aortic valves suggests that specific elastic fiber components may 
function in distinct ways resulting in a spectrum of disease processes. Finally, these data 
suggest that the annulus and ring spongiosa regions, where both shear and oscillatory 
stresses are concentrated and EFF and angiogenesis occur, are important in the manifes-
tation of AVD. EFF and aberrant angiogenesis represent two disease processes that may 
be identifiable and modifiable early in the clinical course of AVD. 
The prevailing view is that AVD is an inflammatory process, commonly associated 
with atherosclerosis, similar to wound healing response. In this context, tissue injury leads 
to inflammation and myofibroblast activation, which in turn leads to fibrosis and neovas-
cularization [42]. Findings from previous studies support an inflammatory mechanism in 
the context of end-stage AVD [11,15], but it is unclear whether this represents the inciting 
pathology or a secondary factor that accelerates AVD progression [43,44]. Increasing evi-
dence suggests additional mechanisms contribute to early AVD pathogenesis, including 
dysregulation of developmental programs [7,45–49], which may predispose valve tissue 
to inflammation. A strength of this current study is the strategy to compare early with 
late-onset AVD specimens [20,21] to control for the confounding effects of common 
comorbidities associated with inflammation in adulthood, including aging [50]. Here we 
have shown for the first time that EFF and aberrant angiogenesis occur in early-onset AVD 
in the absence of inflammation in valve tissue. 
Figure 4. Ultrastructure of the valve a nulus and cusp regions i . ol agen and elastic fiber organization i
annulus (A–C) and cusp (D–F) regions from control (A, ), ( S ( ,F) specimens. Cross ections of collagen
fibr l size and organization are de o st (i sets). In control specimens, organized lastic fiber filaments are een in the
cusp (arrows) but not the annulus. WS specimens are characterized primarily by intra-EFF (B,E), whereas MFS has more
inter-EFF (data not shown). There is proteoglycan accumulation in WS specimens (arrowheads, (B,E)) and a “moth-eaten”
edge appearance in MFS specimens (arrowheads, (C) and (F)). Collagen fibrils are small, irregular, and decreased in number
in the cusp region of WS and the annulus region of MFS (asterisks, (C) and (E)).
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4. Discussion
The findings of this study identify EFF and aberrant angiogenesis as early disease
processes underlying AVD preceding the manifestation of inflammation (Figure 5). These
results establish a central role for elastic fiber dysregulation in early AVD pathogenesis,
suggesting that faulty elastic fiber assembly and consequent elastase-mediated tissue injury
contribute to disease initiation and progression. The demonstration of different types of EFF
in WS and MFS aortic valves suggests that specific elastic fiber components may function
in distinct ways resulting in a spectrum of disease processes. Finally, these data suggest
that the annulus and ring spongiosa regions, where both shear and oscillatory stresses are
concentrated and EFF and angiogenesis occur, are important in the manifestation of AVD.
EFF and aberrant angiogenesis represent two disease processes that may be identifiable
and modifiable early in the clinical course of AVD.
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nodules seen in the valve annulus of the elastin haploinsufficient mouse model of AVD 
[64,65]. The STJ in WS patients is characterized by fibrous overgrowth, in addition to dra-
matic thickening of the aortic media, suggesting that the left ventricular outflow tract ob-
struction seen in SVAS is due in part to valve disease processes. These results suggest that 
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lines, (B). EFF causes angiogenesis (red circles), increased cell proliferation, and matrix accumulation
(C), ultimately leading to inflammation (purple stars) and calcification (black nodules, D).
Los of balance between elastase and elastase inhibitors has been identified as one
cause of EFF, specifically the actual fragmentation of a previously normal elastic fiber
in the context of both aging (physiol ic) ( at ologic) [51–53]. Inflammation
is characterized in part by elastoly is and E F, which explains why these findings are
considered end-stage structural findings; however, several lines of evidence suggest EFF
may precede inflammation through known signaling functions [54,55], including neu-
trophil chemotaxis [25], identifying a potential link between EFF and pre-inflammatory
processes. Furthermore, previous studies have shown that different elastic fiber fragments
have different biologic functions; for example, some fragments induce calcification while
others are chemo-attractants for endothelial cells [56,57]. Consistent with this idea, we
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have demonstrated aberrant angiogenesis in WS but not MFS aortic valves, suggesting
elucidation of different elastic fiber fragment functions may identify new mechanisms
underlying early AVD [58].
Gross and Kugel described the anatomy of mature heart valves in detail, noting the
presence of elastic fiber components in the annulus, ring spongiosa, and fibrosa, in addition
to organized elastic fiber filaments in the ventricularis [29]. In the present study, EFF and
angiogenesis were demonstrated predominantly in the ring spongiosa and proximal aspect
of the cusp, supporting previous observations suggesting that disease begins and worsens
in the hinge area [32,43,59]. The annulus and ring spongiosa regions are especially prone to
degeneration due to secondary insults, such as shear and compressive stresses [60–62]. Woo
et al. elegantly demonstrated a complex interaction between developmental programs that
predispose tissue to disease and shear stresses that trigger inflammation [63], providing
an example of how these factors together contribute to AVD. Elastic fiber lamellae, the
circumferential organizational unit of the ascending aorta, are disrupted in the aortic root
by valve tissue due to the valve annulus’s irregular crown shape, which extends distally to
the STJ. Interestingly, we observed a discrete string of cartilage-like halo cells separating
the fibrous valve annulus tissue from the aortic media in the STJ (the site of obstruction in
SVAS), similar in composition and location to cartilage nodules seen in the valve annulus
of the elastin haploinsufficient mouse model of AVD [64,65]. The STJ in WS patients is
characterized by fibrous overgrowth, in addition to dramatic thickening of the aortic media,
suggesting that the left ventricular outflow tract obstruction seen in SVAS is due in part to
valve disease processes. These results suggest that focused examination of the annulus and
ring spongiosa regions in both human and animal research will inform our understanding
of AVD progression.
Both early and late-onset AVD is characterized by EFF. Our findings suggest that some
elastic fiber fragments, or specific types of EFF, result in aberrant angiogenesis, underscor-
ing the importance of delineating elastic fiber development [66]. Since our understanding
of human AVD pathogenesis is limited to observations in late-stage disease, animal models
are necessary to identify mechanisms that contribute to early pathogenesis. Targeted muta-
genesis of elastic fiber genes in mice has generated models characterized in part by valve
phenotypes, including elastin, emilin-1, fibrillin-1, and fibulin-4 [64,67–69]. Likewise, genes
that regulate angiogenesis, including VEGF, chondromodulin, and periostin, also play a
role in valve development and disease [70–72]. The emilin-1 mutant mouse model of AVD
demonstrates both EFF and aberrant angiogenesis [67], but the elastin haploinsufficent
mouse model of AVD does not [64]. Other elastic fiber mouse models have been associated
with pro-angiogenic effects or vasculature defects, but they have not reported on the poten-
tial presence of neovessels in valve tissue [55]. EFF and angiogenesis represent two early
disease processes that may lead to new pharmacologic-based treatment strategies.
Presently, there are no pharmacologic-based treatment strategies for AVD. Clinical
studies have identified risk factors for AVD progression, but studies examining human
AVD tissue are restricted to late-stage disease. As a result, our understanding of early patho-
genesis is limited. The observation that EFF and angiogenesis are early disease processes
suggests that elastase and angiogenesis inhibitors represent potential new pharmacologic
treatments for AVD that prevent disease progression and the need for surgery [8,73]. While
nonspecific clinical risk factors for AVD have been established [36], predictive biomarkers
have not been identified for early AVD progression. Aortic valve sclerosis, or thickening of
the aortic valve, is a late marker of cardiovascular risk but not a specific marker for AVD [74].
The systemic effects of EFF and aberrant angiogenesis in valve tissue may provide these
specific biomarkers, such as an increase in specific types of urine elastin degradation prod-
ucts. Finally, a better understanding of EFF-induced cell-matrix perturbations may inform
the search for durable valve bioprostheses [75].
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